Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
238.66
-7.48 (-3.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ascendis (ASND) Q2 2025 Earnings Call Transcript
↗
August 07, 2025
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 06, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 04, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 28, 2025
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
July 22, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 07, 2025
Via
Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
↗
July 03, 2025
Via
Benzinga
Is Ascendis Pharma Gaining or Losing Market Support?
↗
June 03, 2025
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 29, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
June 12, 2025
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 21, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
↗
May 06, 2025
Via
Benzinga
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
↗
May 05, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
↗
April 30, 2025
Via
Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
↗
March 04, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
February 19, 2025
Via
Benzinga
Earnings Scheduled For February 12, 2025
↗
February 12, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
January 23, 2025
Via
Benzinga
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria
↗
April 28, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?
Via
Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
April 15, 2025
Via
Benzinga
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock?
↗
April 04, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via
Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
↗
March 26, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
↗
March 25, 2025
Via
Benzinga
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?
↗
March 14, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).
Via
Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
↗
January 15, 2025
Via
Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
↗
February 20, 2025
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Via
Benzinga
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
↗
February 13, 2025
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Via
Benzinga
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
↗
February 13, 2025
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
